SCHEMBL3074282

SCHEMBL3074282

Cc1nc(-c2ccc(CO)s2)cs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.48
ALDH1A1 P00352 6/20 0.46
MAPT P10636 5/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HPGD P15428 2/20 0.46
GLA P06280 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
DPP4 P27487 1/20 0.45
HSD17B10 Q99714 2/20 0.44
NPC1 O15118 2/20 0.43
GFER P55789 1/20 0.43
POLB P06746 3/20 0.42
GAA P10253 2/20 0.42
RECQL P46063 1/20 0.42
ESR2 Q92731 1/20 0.42
CYP2A6 P11509 1/20 0.42
KLKB1 P03952 1/20 0.42
KLK1 P06870 1/20 0.42
RAB9A P51151 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3823188 0.83 KDM4E (0.48) KDM4EALDH1A1MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL3821911 0.81 CYP2A6 (0.48) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL9093912 0.79 ALDH1A1 (0.46) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL423483 0.77 MAPT (0.68) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL13680910 0.76 KDM4E (0.46) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL10211630 0.74 KDM4E (0.46) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL12919391 0.73 KMT2A (0.44) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL4160754 0.73 KDM4E (0.54) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL8572801 0.72 MEN1 (0.70) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL8571719 0.72 DPP4 (0.56) ALDH1A1MAPTMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110372692-B Dihydroquinazolinone reverse transport process blocker, and preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2020-10-23 CN disclosed
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
EP-2096111-A1 PYRAZOLES AND USE THEREOF AS DRUGS Japan Tobacco Inc. (JP) 2009-09-02 EP disclosed
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF JAPAN TOBACCO, INC. (JP) 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE AR, NR5A1, NR3C2 KDM4E 1414/4885ALDH1A1 809/4885MAPT 4236/4885
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF PYGL, GYS2, G6PC1 KDM4E 1955/4885ALDH1A1 775/4885MAPT 2112/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 KDM4E 1440/4885ALDH1A1 816/4885MAPT 4248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.